Literature DB >> 20119656

[Anti-NMDA-receptor encephalitis. An interdisciplinary clinical picture].

H Prüss1, J Dalmau, V Arolt, K-P Wandinger.   

Abstract

Anti-NMDA-receptor encephalitis is a severe and considerably underdiagnosed form of encephalitis with characteristic clinical features including psychiatric symptoms, decreased levels of consciousness, hypoventilation, epileptic seizures, autonomic dysfunction and dyskinesias. Most patients are primarily seen by psychiatrists, often on the assumption of a drug-induced psychosis. Anti-NMDA-receptor encephalitis had initially been described in young women with ovarian teratoma, but is also common in women without tumour, in men and in children. The diagnosis is based on the characteristic clinical picture, supporting findings of brain MRI, electroencephalogram and cerebrospinal fluid (CSF), and the presence of highly specific autoantibodies directed against the NR1 subunit of NMDA-type glutamate receptors in the serum or CSF. In particular, anti-NMDA-receptor encephalitis must be excluded in patients with 'encephalitis of unknown cause'. In principle, the prognosis is favourable and recovery from symptoms can be expected even after prolonged intensive care treatment and mechanical ventilation. However, improvement correlates with prompt identification of the disorder, early immunotherapy and - in the case of a malignancy - with complete tumour removal. Patient care requires an interdisciplinary approach including neurologists, psychiatrists, paediatricians, oncologists and gynaecologists.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20119656     DOI: 10.1007/s00115-009-2908-9

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  38 in total

Review 1.  Antibodies in myasthenia gravis and related disorders.

Authors:  Angela Vincent; John McConville; Maria Elena Farrugia; John Bowen; Paul Plested; Teresa Tang; Amelia Evoli; Ian Matthews; Gary Sims; Paolo Dalton; Leslie Jacobson; Agata Polizzi; Frans Blaes; Bethan Lang; David Beeson; Nick Willcox; John Newsom-Davis; Werner Hoch
Journal:  Ann N Y Acad Sci       Date:  2003-09       Impact factor: 5.691

Review 2.  Human herpesvirus 6: a clinical update.

Authors:  Danielle M Zerr
Journal:  Herpes       Date:  2006-05

3.  "Limbic encephalitis" and its association with carcinoma.

Authors:  J A Corsellis; G J Goldberg; A R Norton
Journal:  Brain       Date:  1968-09       Impact factor: 13.501

4.  A serologic marker of paraneoplastic limbic and brain-stem encephalitis in patients with testicular cancer.

Authors:  R Voltz; S H Gultekin; M R Rosenfeld; E Gerstner; J Eichen; J B Posner; J Dalmau
Journal:  N Engl J Med       Date:  1999-06-10       Impact factor: 91.245

5.  Anti-NMDA receptor encephalitis in Japan: long-term outcome without tumor removal.

Authors:  T Iizuka; F Sakai; T Ide; T Monzen; S Yoshii; M Iigaya; K Suzuki; D R Lynch; N Suzuki; T Hata; J Dalmau
Journal:  Neurology       Date:  2007-09-26       Impact factor: 9.910

6.  A single application of MK801 causes symptoms of acute psychosis, deficits in spatial memory, and impairment of synaptic plasticity in rats.

Authors:  Denise Manahan-Vaughan; Dorothea von Haebler; Christine Winter; Georg Juckel; Uwe Heinemann
Journal:  Hippocampus       Date:  2008       Impact factor: 3.899

Review 7.  Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence.

Authors:  P J Harrison; D R Weinberger
Journal:  Mol Psychiatry       Date:  2005-01       Impact factor: 15.992

8.  Clinical, magnetic resonance imaging, and electroencephalographic findings in paraneoplastic limbic encephalitis.

Authors:  Nicholas D Lawn; Barbara F Westmoreland; Michael J Kiely; Vanda A Lennon; Steven Vernino
Journal:  Mayo Clin Proc       Date:  2003-11       Impact factor: 7.616

9.  Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis.

Authors:  Angela Vincent; Camilla Buckley; Jonathan M Schott; Ian Baker; Bonnie-Kate Dewar; Niels Detert; Linda Clover; Abigail Parkinson; Christian G Bien; Salah Omer; Bethan Lang; Martin N Rossor; Jackie Palace
Journal:  Brain       Date:  2004-02-11       Impact factor: 13.501

Review 10.  Glutamate and dopamine dysregulation in schizophrenia--a synthesis and selective review.

Authors:  James M Stone; Paul D Morrison; Lyn S Pilowsky
Journal:  J Psychopharmacol       Date:  2007-01-26       Impact factor: 4.153

View more
  15 in total

1.  [Anti-NMDA receptor encephalitis: an important differential diagnosis of catatonia in young psychiatric patients].

Authors:  D Stanischewski; A Borchert; M Marziniak; V Arolt; F Kästner
Journal:  Nervenarzt       Date:  2013-07       Impact factor: 1.214

2.  [Therapeutic options for autoimmune encephalomyelitis].

Authors:  N Borisow; H Prüss; F Paul
Journal:  Nervenarzt       Date:  2013-04       Impact factor: 1.214

Review 3.  Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis.

Authors:  Josep Dalmau; Eric Lancaster; Eugenia Martinez-Hernandez; Myrna R Rosenfeld; Rita Balice-Gordon
Journal:  Lancet Neurol       Date:  2011-01       Impact factor: 44.182

Review 4.  [Update on anti-N-methyl-D-aspartate receptor encephalitis].

Authors:  S Kovac; J Alferink; D Ahmetspahic; V Arolt; N Melzer
Journal:  Nervenarzt       Date:  2018-01       Impact factor: 1.214

5.  [Therapeutic apheresis for autoimmune encephalitis: a nationwide data collection].

Authors:  S Ehrlich; C M Fassbender; C Blaes; C Finke; A Günther; L Harms; F Hoffmann; K Jahner; R Klingel; A Kraft; T Lempert; M Tesch; J Thomsen; H Topka; J Jochim; C Veauthier; W Köhler
Journal:  Nervenarzt       Date:  2013-04       Impact factor: 1.214

Review 6.  Glutamate receptor antibodies in neurological diseases: anti-AMPA-GluR3 antibodies, anti-NMDA-NR1 antibodies, anti-NMDA-NR2A/B antibodies, anti-mGluR1 antibodies or anti-mGluR5 antibodies are present in subpopulations of patients with either: epilepsy, encephalitis, cerebellar ataxia, systemic lupus erythematosus (SLE) and neuropsychiatric SLE, Sjogren's syndrome, schizophrenia, mania or stroke. These autoimmune anti-glutamate receptor antibodies can bind neurons in few brain regions, activate glutamate receptors, decrease glutamate receptor's expression, impair glutamate-induced signaling and function, activate blood brain barrier endothelial cells, kill neurons, damage the brain, induce behavioral/psychiatric/cognitive abnormalities and ataxia in animal models, and can be removed or silenced in some patients by immunotherapy.

Authors:  Mia Levite
Journal:  J Neural Transm (Vienna)       Date:  2014-08-01       Impact factor: 3.575

7.  Seroprevalence of anti-N-methyl-D-aspartate receptor antibodies in women with ovarian teratoma.

Authors:  Mandy Mangler; Isabel Trebesch de Perez; Bianca Teegen; Winfried Stöcker; Harald Prüss; Andreas Meisel; Achim Schneider; Jekaterina Vasiljeva; Dorothee Speiser
Journal:  J Neurol       Date:  2013-08-24       Impact factor: 4.849

8.  Uncommon cause of psychotic behavior in a 9-year-old girl: a case report.

Authors:  Willemina K Van Putten; Said Hachimi-Idrissi; Anna Jansen; Viola Van Gorp; Luc Huyghens
Journal:  Case Rep Med       Date:  2012-12-18

9.  Immunological findings in psychotic syndromes: a tertiary care hospital's CSF sample of 180 patients.

Authors:  Dominique Endres; Evgeniy Perlov; Annette Baumgartner; Tilman Hottenrott; Rick Dersch; Oliver Stich; Ludger Tebartz van Elst
Journal:  Front Hum Neurosci       Date:  2015-09-10       Impact factor: 3.169

10.  Hypoglutamatergic state is associated with reduced cerebral glucose metabolism in anti-NMDA receptor encephalitis: a case report.

Authors:  Dominique Endres; Evgeniy Perlov; Oliver Stich; Sebastian Rauer; Simon Maier; Zora Waldkircher; Thomas Lange; Irina Mader; Philipp Tobias Meyer; Ludger Tebartz van Elst
Journal:  BMC Psychiatry       Date:  2015-08-01       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.